Paritaprevir/Ombitasvir/Ritonavir
Tier C — Watch / tradeParitaprevir/Ombitasvir/Ritonavir
Targets：HIV-1 protease, NS5A, NS3/NS4A
Brand：Technivie, Viekirax, Qurevo
Indications (approved)：Chronic hepatitis C, Hepatitis C
Regional status
Factories producing this API9
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
9 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates3 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| RITO-001 | 6372-14-1 | (S)-benzyl (1-hydroxy-3-phenylpropan-2-yl)carbamate |
| RITO-002 | 59830-60-3 | (S)-benzyl (1-oxo-3-phenylpropan-2-yl)carbamate |
| RITO-003 | 137649-69-5 | dibenzyl ((2S,3R,4R,5S)-3,4-dihydroxy-1,6-diphenylhexane-2,5-diyl)dicarbamate |
| RITO-004 | 40635-67-4 | 1-bromo-2-methyl-1-oxopropan-2-yl acetate |
| RITO-005 | - | (5S,6R,7R,8S)-5,8-dibenzyl-7-bromo-3,10-dioxo-1,12-diphenyl-2,11-dioxa-4,9-diazadodecan-6-yl acetate |
| RITO-006 | 177469-39-5 | dibenzyl ((1S,1'S)-((2R,3R)-oxirane-2,3-diyl)bis(2-phenylethane-1,1-diyl))dicarbamate |
| RITO-007 | 144141-68-4 | dibenzyl ((2S,3S,5S)-3-hydroxy-1,6-diphenylhexane-2,5-diyl)dicarbamate |
| RITO-008 | 144163-44-0 | (2S,3S,5S)-2,5-diamino-1,6-diphenylhexan-3-ol |
| RITO-009 | 98-80-6 | phenylboronic acid |
| RITO-010 | 165315-39-9 | (S)-1-((4S,6S)-4-benzyl-2-phenyl-1,3,2-oxazaborinan-6-yl)-2-phenylethanamine |
| RITO-011 | 144163-97-3 | 4-nitrophenyl (thiazol-5-ylmethyl) carbonate |
| RITO-012 | 144164-11-4 | thiazol-5-ylmethyl ((2S,3S,5S)-5-amino-3-hydroxy-1,6-diphenylhexan-2-yl)carbamate |
| RITO-013 | 154212-61-0 | (S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoic acid |
| RITO-014 | 105-39-5 | ethyl 2-chloroacetate |
| RITO-015 | 33142-21-1 | ethyl 2-chloro-3-oxopropanoate |
| RITO-016 | 115-08-2 | methanethioamide |
| RITO-017 | 32955-22-9 | ethyl thiazole-5-carboxylate |
| RITO-018 | 38585-74-9 | thiazol-5-ylmethanol |
| RITO-019 | 7693-46-1 | 4-nitrophenyl carbonochloridate |
| RITO-020 | 563-83-7 | isobutyramide |
| RITO-021 | 13515-65-6 | 2-methylpropanethioamide |
| RITO-022 | 534-07-6 | 1,3-dichloropropan-2-one |
| RITO-023 | 6306-52-1 | methyl L-valinate hydrochloride |
| RITO-024 | 154212-60-9 | 1-(2-isopropylthiazol-4-yl)-N-methylmethanamine |
| RITO-025 | 162537-10-2 | - |
| RITO-026 | 154248-99-4 | (S)-methyl 2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoate |
| Code | CAS No. | Intermediate |
|---|---|---|
| RITO-011 | 144163-97-3 | 4-nitrophenyl (thiazol-5-ylmethyl) carbonate |
| RITO-012 | 144164-11-4 | thiazol-5-ylmethyl ((2S,3S,5S)-5-amino-3-hydroxy-1,6-diphenylhexan-2-yl)carbamate |
| RITO-013 | 154212-61-0 | (S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-3-methylbutanoic acid |
| RITO-027 | 63-91-2 | L-phenylalanine |
| RITO-028 | 111138-83-1 | (S)-benzyl 2-(dibenzylamino)-3-phenylpropanoate |
| RITO-029 | 6921-34-2 | benzylmagnesium chloride |
| RITO-030 | 156732-13-7 | (S,E)-5-amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one |
| RITO-031 | 156732-15-9 | (2S,3S,5S)-5-amino-2-(dibenzylamino)-1,6-diphenylhexan-3-ol |
| RITO-032 | 162849-93-6 | tert-butyl ((2S,4S,5S)-5-(dibenzylamino)-4-hydroxy-1,6-diphenylhexan-2-yl)carbamate |
| RITO-033 | 169870-02-4 | tert-butyl ((2S,4S,5S)-5-amino-4-hydroxy-1,6-diphenylhexan-2-yl)carbamate succinate |
| Code | CAS No. | Intermediate |
|---|---|---|
| RITO-027 | 63-91-2 | L-phenylalanine |
| RITO-033 | 169870-02-4 | tert-butyl ((2S,4S,5S)-5-amino-4-hydroxy-1,6-diphenylhexan-2-yl)carbamate succinate |
| RITO-034 | 3182-95-4 | (S)-2-amino-3-phenylpropan-1-ol |
| RITO-035 | 749167-08-6 | (S)-1-chloro-3-phenylpropan-2-amine |
| RITO-036 | 403735-04-6 | (S)-tert-butyl (1-chloro-3-phenylpropan-2-yl)carbamate |
| RITO-037 | 172695-25-9 | (S)-tert-butyl (1-cyano-3-phenylpropan-2-yl)carbamate |
| RITO-038 | 72155-45-4 | (S)-tert-butyl (1-oxo-3-phenylpropan-2-yl)carbamate |
| RITO-039 | 6125-24-2 | (2-nitroethyl)benzene |
| RITO-040 | 1360824-68-5 | tert-butyl ((2S,4S,5S)-4-hydroxy-5-nitro-1,6-diphenylhexan-2-yl)carbamate |
| RITO-041 | 144163-85-9 | tert-butyl ((2S,4S,5S)-5-amino-4-hydroxy-1,6-diphenylhexan-2-yl)carbamate |
Frequently asked questions
What are the approved indications of Paritaprevir/Ombitasvir/Ritonavir?
Approved indications include: Chronic hepatitis C, Hepatitis C.
When does the Paritaprevir/Ombitasvir/Ritonavir patent expire?
No public expiry year is available for Paritaprevir/Ombitasvir/Ritonavir yet; this page updates once verified.
How many synthesis routes are recorded for Paritaprevir/Ombitasvir/Ritonavir?
3 synthesis routes are recorded; the shortest is 7 steps with 2.60 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Paritaprevir/Ombitasvir/Ritonavir intermediates?
All intermediates in Paritaprevir/Ombitasvir/Ritonavir routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Paritaprevir/Ombitasvir/Ritonavir intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29